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Abstract
Mononuclear phagocytes are considered to be main targets for Dengue Virus (DENV) replication.
These cells are activated after infection, producing proinflammatory mediators, including tumour-
necrosis factor-α, which has also been detected in vivo. Nitric oxide (NO), usually produced by
activated mononuclear phagocytes, has antimicrobial and antiviral activities.
Methods
The expression of DENV antigens and inducible nitric oxide synthase (iNOS) in human blood
isolated monocytes were analysed by flow cytometry using cells either from patients with acute
Dengue Fever or after DENV-1 in vitro infection. DENV-1 susceptibility to iNOS inhibition and NO
production was investigated using NG-methyl L-Arginine (NGMLA) as an iNOS inhibitor, which was
added to DENV-1 infected human monocytes, and sodium nitroprussiate (SNP), a NO donor,
added to infected C6/36 mosquito cell clone. Viral antigens after treatments were detected by flow
cytometry analysis.
Results
INOS expression in activated monocytes was observed in 10 out of 21 patients with Dengue Fever
and was absent in cells from ten healthy individuals. DENV antigens detected in 25 out of 35
patients, were observed early during in vitro infection (3 days), significantly diminished with time,
indicating that virus replicated, however monocytes controlled the infection. On the other hand,
the iNOS expression was detected at increasing frequency in in vitro infected monocytes from three
to six days, exhibiting an inverse relationship to DENV antigen expression. We demonstrated that
the detection of the DENV-1 antigen was enhanced during monocyte treatment with NGMLA. In
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the mosquito cell line C6/36, virus detection was significantly reduced in the presence of SNP, when
compared to that of untreated cells.
Conclusion
This study is the first to reveal the activation of DENV infected monocytes based on induction of
iNOS both in vivo and in vitro, as well as the susceptibility of DENV-1 to a NO production.
Background
Dengue viruses (DENV) have been detected in several
lymphoid organs originating from fatal cases of hemor-
rhagic disease, mainly in cells from the mononuclear
phagocyte lineage [1]. Nevertheless, the frequency of dis-
seminated virus detection in autopsies is low and micro-
scopic injury is not sufficient to justify death during the
Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syn-
drome (DSS). It is believed that disease severity is a result
of an immunopathological response leading to hemor-
rhagic and vasodynamic alterations and shock.
Mononuclear phagocytes have been considered as main
targets for DENV replication [2,3] and recently the virus
was detected in dendritic cells originating from one indi-
vidual 24 hours post DENV infection [4,5]. Morens et al.
[6] have shown strain differences of DENV, originating
either from mild or severe cases, with respect to their
growth in human monocytes, suggesting that characteris-
tics inherent to virus genome and replication were related
with disease severity. Viral RNA was detected by RT-PCR
in peripheral blood leukocytes [7] in humans during
infection and DENV antigens were present in circulating
monocytes [8], Kupffer cells and macrophages from dif-
ferent organs such as liver, spleen and lungs [9].
Pathogenesis may consist of virus penetration into mono-
cytes or dendritic cells, cell activation and synthesis induc-
tion of cytokines, arachdonic acids and very likely nitric
oxide. These factors would be involved not only in gener-
ating dengue disease [10] but also in the elimination of
viruses [11].
The in vivo activation of mononuclear phagocytes by inter-
feron (IFN)-γ during DENV infection can be expected,
since this cytokine is detected in serum during the acute
phase [12,13] and is also produced by peripheral leuko-
cytes from patients with previous dengue records [14]
The  in vitro production of IFN-α,β, interleukin-6 and
tumour-necrosis factor (TNF)-α by infected fibroblasts
and/or macrophages was described [15] as well as the pro-
duction of platelet activating factors [16]. Recently, viral
titres during infection were correlated with the production
of prostaglandin E2, which is known to be vasoactive [17].
Considering that dengue is an acute and short-termed dis-
ease, and IFN-α,β and TNF-α are molecules that induce
antiviral defence mechanisms [11], it is conceivable that
DENV replication is greatly inhibited in mononuclear
phagocytes, although inflammatory reactions may be acti-
vated as well. It is well known that NO is produced by
IFN-γ activation of monocytes [18] and has antiviral activ-
ities against Herpes Simplex Viruses, Epstein Bar Virus and
some Coxsackie and Tick-borne encephalitis viruses [16].
NO levels were found to be increased in patients with den-
gue [19] or in vitro infected Kupffer cells [20], however
the production has not been detected in infected mono-
cytes in culture [21].
The aim of this research is to investigate iNOS monocyte
induction during acute DENV infection in patients and
after in vitro infection by DENV-1. We demonstrated that
monocytes isolated from several patients became acti-
vated and express iNOS, which leads to the production of
NO by the cell. DENV-1 was susceptible to a NO donor
treatment and, in addition, virus was detected at higher
rates in infected cells after iNOS inhibition, indicating
that NO might play a substantial role in controlling
DENV-1 infection of monocytes in culture and in vivo
during natural infection.
Methods
Patients and laboratory diagnosis
Blood samples were obtained from DENV infected
patients in April 2000 in Foz do Iguaçu, PR, and from Feb-
ruary to April 2001 and January to March 2002 in Niterói,
RJ, Brazil. Patients were diagnosed based on clinical
grounds as Dengue Fever (fever, headache, retro-orbital
pain, mialgias, arthralgias, rash and prostration); some
had hemorrhagic manifestations, platelet counts under
100,000/mm3, hypotension receiving parenteral hydra-
tion and hospitalisation. The diagnosis of DENV infection
was confirmed by anti-dengue enzyme-linked immuno-
sorbent assay (ELISA)-IgM, or virus isolation. Informed
written consent, approved by Fundação Oswaldo CruzBMC Infectious Diseases 2005, 5:64 http://www.biomedcentral.com/1471-2334/5/64
Page 3 of 12
(page number not for citation purposes)
Ethical Committee under Nr#111/00, was obtained from
all dengue patients prior to blood draw.
Cell cultures
Aedes albopictus C6/36 cell clone was grown as monolayers
at 34°C on Leibovitz medium (L-15) supplemented with
200 mM glutamine, 1% non-essential amino acids solu-
tion, 19% tryptose phosphate broth, 100 U/ml penicillin,
10 µg/ml streptomycin and 5% foetal calf serum (FCS).
Preparation of virus stock and virus titration
DENV serotype 1, strain 16007 was provided by Dr. SB
Halstead (Naval Medical Research Center, USA). Virus
was titrated by serial dilution cultures in microtiter plates
and detected by immunofluorescence as previously
described [22]. Virus titre was calculated as 50 percent tis-
sue culture infectious dose or TCID50/ml [23,24]. Inacti-
vated virus was prepared by incubating the inoculum for
24 hours at 37°C and treating it with UV light (60 Hz,
with distance of 20 cm) for 1 hour. Virus stock used was
at a concentration of 3.18 × 107 TCID50/ml.
Preparation of human peripheral blood mononuclear 
leukocytes (PBMLs)
Mononuclear leukocytes were obtained from heparinised
venous blood originating from either DENV-infected
patients or dengue seronegative adult donors. Cells were
isolated through density gradient centrifugation (350 g,
20 minutes in Ficoll-Paque Plus Amersham Biosciences
Corp, Piscataway, USA). Cells were suspended in RPMI
1640 supplemented with 200 mM glutamine, 100 U/ml
penicillin, 10 µg/ml streptomycin and 10% FCS and after-
wards incubated at 37°C under humid atmosphere with
5%CO2. Cells isolated from patients with acute dengue
were suspended in supplemented RPMI 1640 containing
an additional 10% DMSO and 50% FCS and maintained
in liquid nitrogen.
Infection of adherent PBMLs and treatment with an iNOS 
inhibitor
Infections were performed on 24-well plates. Freshly iso-
lated PBML suspended in RPMI 1640 medium and sup-
plemented with 10% FCS were seeded at 2 × 106cells/well.
After an 18 hour-incubation, adherent cells were enriched
by washing away unattached cells twice. Inoculum was
diluted in 1 ml medium containing a multiplicity of infec-
tion approximately of 8 TCID50/adherent cell DENV-1.
After a 2 hour-incubation for adsorption, 1 ml medium
was added to achieve 10% FCS. After an 18 hour-incuba-
tion, all culture medium containing virus was removed
and cultures were further incubated with fresh medium
for up to 6 days. In some experiments the iNOS inhibitor,
NG-methyl L-Arginine (NGMLA), was added at a final con-
centration of 400 µM. Wells were set in triplicates for each
different parameter in culture. Cell viability was deter-
mined in culture by Trypan blue exclusion during 6 days.
Duplicates of cell control, inactivated and infectious
DENV were assayed. Viability ratios were calculated by
dividing cell counts from each day by counts made just
after virus adsorption.
Infection of C6/36 cell line and treatment with a NO donor
Infections were performed on 24-well plates. C6/36 were
seeded at 2 × 105 cells/well in medium with 5% FCS and
allowed to form a monolayer for 24 h at 34°C. Cell super-
natant was removed and adherent cells were washed twice
with medium without FCS. Wells were filled with 1 ml
fresh medium containing DENV-1 or only medium in a
1:10 dilution from initial inoculum containing a multi-
plicity of infection of 1.59 TCID50 / cell for DENV-1. After
a 90 minute-adsorption, 1.0 ml medium was added to
achieve 2% FCS, containing sodium nitroprussiate (SNP),
a NO donor, resulting in final concentrations of 10 or 100
µM [25]. Viruses were allowed to grow for two days in
incubated cultures. Triplicate wells were set for each cul-
ture parameter. Viability of treated cells was confirmed by
Trypan blue exclusion or propidium iodine uptake.
Virus labelling of infected C6/36 cells, single and double 
labelling of infected adherent PBMLs for flow cytometry 
analysis
Cells were recovered by scratching with plastic microtip
using cold medium and were set at 1 × 106/microtube;
they were centrifuged (350 g, 5 min) and washed once
with 1 ml PBS pH 7.4 with 2% FCS and 0,01% NaN3. Sur-
face labelling was performed with FITC-labelled antibod-
ies to CD14 (DAKO, Denmark, 1:100 dilution) for 45
min directly on adherent viable PBMLs under ice bath.
This was done to confirm that ~95% of the monocyte
gated cells would be CD14+ on the infection day. Intrac-
ellular staining after infection was performed according to
previously described [26] with slight modifications.
Briefly, it required a fixation with 0.5 ml cold paraformal-
dehyde at 4% in PBS for 10 min and, after centrifugation,
membrane permeabilization was carried out with 1 ml
0.1% saponine in PBS with FCS and NaN3. Monoclonal
antibody Dengue Complex-reactive (Chemicon, USA,
1:200 dilution in PBS with saponine, FCS and NaN3) was
added to cells for a 60-minute incubation. Cells were
washed once with 1 ml PBS with FCS and NaN3 and fur-
ther incubated with anti-mouse IgG labelled with PE or
FITC (DAKO, USA, 1:50 dilution in PBS with saponine,
FCS and NaN3) for 30 minutes. After washing, infected
adherent PBMLs were further incubated with FITC-
labelled antibody to iNOS (B&D Transduction Laborato-
ries, USA, 1:100 dilution) for 45 minutes. Alternatively,
for double staining CD14 and DENV, cells were firstly
labelled with PE-labelled antibodies to CD14 (DAKO at
dilution 1:100) for 30 minutes 4°C, washed, fixed with
0,5 ml cold 2% paraformaldehyde for 10 minutes and,BMC Infectious Diseases 2005, 5:64 http://www.biomedcentral.com/1471-2334/5/64
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after centrifugation, membrane permeabilization was car-
ried out with 1 ml 0.1% saponine PBS with FCS and NaN3
and further labelled with Alexa 654 – labelled mono-
clonal antibody to Dengue for 30 minutes. Matching iso-
type antibodies were used for DENV and iNOS labelings.
Finally cells were washed twice, ressuspended in 1% para-
formaldehyde and kept at 4°C up to 3 days until acquisi-
tion by flow cytometry. Cells were acquired (10,000
events for cell lines and 5,000 for gated monocytes) on a
FACS® Calibur flow cytometer (Beckon & Dickinson, USA)
and analysed using FlowJo Software (TreeStar Inc., CA,
USA). Isotype-matched antibodies were used as a negative
control for all stainings.
Statistical analyses
Two-way Student's t test was performed using GraphPad
Prism version 4.02 for Windows, GraphPad Software (San
Diego, CA, USA, http://www.graphpad.com) in order to
determine the significance of differences in percentages of
virus labelling found in cells infected under various con-
ditions. Altered parameters were considered significant
when P < 0.05.
Labelled cell rates in healthy donors were firstly tested for
normality using the Prism program (values passed the
normality test of Kolmogorow-Smirnov) and then cell
patient frequencies were tested for sample positivity by
Student's t-Distribution (tn-1 = 10, α = 0.025 = 2.228 or tn-1 = 9,
α = 0.025 = 2.262) calculating a referential limit value for
negativity, according to the following formula: Average of
values from control samples + [Standard Deviation of values
from control samples X t(n-1;α = 0.025)]. Determinations above
referential limit values were considered positive.
Results
Characterization of target cells for DENV and iNOS 
expression in peripheral blood mononuclear leukocytes 
(PBMLs) originating from patients with Dengue Fever
Previous reports demonstrated human monocytes as tar-
gets for DENV in cultures [1,27]. Therefore, monocyte and
lymphocyte subsets present in PBMLs originated from
patients with acute Dengue Fever were analysed by flow
cytometry (FACS). Figure 1 displays the cell size and gran-
ularity profiles of PBMLs from a healthy donor (Figure
1A) and a dengue patient (Figure 1C). CD14+ gated cells
were selected (Figure 1B) and plotted as logical monocyte
gate in the FSCxSSC dot plot (R1 in Figure 1C). Monocyte
(R1) and lymphocyte (R2) gates selected were used for
further studies. Approximately 95% cells of the R1 are
CD14+ cells.
The monocyte and lymphocyte profile by FACS after
DENV and iNOS immune-labelling were studied. Repre-
sentative dot plots of DENV Antigens (Ag) and iNOS pos-
itive detection in monocytes from dengue patients
(Figures 1E and 1H, respectively) are compared to mono-
cytes from healthy individuals (Figures 1D and 1G) and
lymphocytes from patients (Figures 1F and 1I). Patient
monocytes presented DENV-Ag during the first eleven
days of disease onset (Figures 1E and 2A) compared to
control monocytes (Figures 1D and 2A). Patient cells col-
lected at later stages of disease did not display detectable
viral antigen (data not shown). Among the 35 dengue
patients 25 expressed DENV-Ag above the referential limit
value for negativity in the Student's t-Distribution and no
difference was detected between early (1–5 days) and late
(6–11 days) infection. Among 22 patients tested for iNOS
expression (Figures 1H and 2B), 10 were positive as com-
pared to controls (Figures 1G and 2B). Cells from the lym-
phocyte gate do express neither DENV-Ag (0.80 ± 0.77%)
nor iNOS (3.7 ± 2.57%) (Figures 1F and 1I, respectively).
The highest incidence of iNOS activation was from 6 to 10
days of disease (8 out of 20 patients). Among 11 patients
with platelet counts<100,000/mm3, six had iNOS+ cells
above the referential limit value for negativity. Seven of
these patients also had hypotension, were hospitalised
and submitted to parenteral rehydration. Among 11
patients with normal platelet levels merely 4 had signifi-
cantly elevated iNOS+ cell ratios. INOS expression, present
in a significant frequency among dengue patients, could
not be associated with severity in this sampling.
Characterization of DENV target cells, DENV-Ag detection 
and iNOS expression in monocytes after in vitro infection
Adherent human PBMLs were incubated for 3–6 days with
infectious and inactivated DENV and evaluated for pres-
ence of DENV-Ag and iNOS expression. Cell viability was
determined daily by Trypan blue exclusion. After 3 days of
culture, cells incubated with the inactivated virus
remained 42 ± 7% viable and with infectious virus 42 ±
23% viable as compared to the day 0. On day 6 37 ± 2%
cells were viable for inactivated and 44 ± 3% for infectious
virus, showing no differences between the two virus incu-
bations. Control cell rates of viability were higher, 58 ±
8% at day 3 and 69 ± 19% at day 6. Although infectious
viruses may not be crucial in increasing monocyte mortal-
ity, viral antigens alter cell viability.
Kinetics of virus detection in mononuclear phagocytes
varies according to virus strain and multiplicity of infec-
tion (MOI) used (Cologna et al., 2003). At the MOI used
here for DENV-1 strain 16007 (8 TCID50/adherent cell)
preliminary results displayed low rates of infection on the
first day (in average 17 ± %), increasing at day 2 (average
31%). No iNOS labelling was detected on these first days
of infection. Therefore, experiments were performed using
infections from 3 to 6 days.
Figure 3B shows an image obtained under confocal micro-
scopy in a field with a high frequency of infected adherentBMC Infectious Diseases 2005, 5:64 http://www.biomedcentral.com/1471-2334/5/64
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Dot and contour plots showing DENV-Ag and iNOS monocyte and lymphocyte expression in dengue patients Figure 1
Dot and contour plots showing DENV-Ag and iNOS monocyte and lymphocyte expression in dengue patients. 
Human PBMLs a from healthy individual (Figures 1A,1D,1G) were used as control. Cells from a 4-day dengue infected patient 
(Figures 1B,1C,1E,1F,1H,1I) were labelled with anti-CD14-PE and CD14+ gated cells – R1 (Figure 1B) were considered as logi-
cal gate or monocyte gate and R2 is as the lymphocyte gate in the FCS vs. SSC dot plot (Figure 1C). R1 and R2 were used for fur-
ther analysis during this work. Alternatively, human PBMLs were labelled either with an antibody to DENV Ags and anti-mouse 
IgG-PE (Figures 1D-1F) or with anti-iNOS-FITC (Figures 1G-1I) and analysed by FACS in either the R1, monocyte gate (Figures 
1D-1F) or in the R2, lymphocyte gate (Figures 1F-1I). x-axis represent mean of cell population size (FCS) and y-axis represent 
cell granularity (SSC) or fluorescence intensity.
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mononuclear leukocytes compared to the absence of flu-
orescent cells in control cells (Figure 3A). DENV-Ag+ cells
were detected by flow cytometry among CD14+  cells,
although very small rates of CD14- cells were also labelled
for DENV-Ag (Figures 4A and 4B are labelling controls for
Figure 4C). For further evaluations during in vitro infec-
tion, we studied the monocyte population, using the
CD14+ logical gate, which presented the same profile as
the R1 shown in Figure 1B).
In Figure 4D we observed that infected monocytes dis-
played specific DENV-Ag expression when compared to
monocyte incubation with inactivated virus and an iso-
type-matched antibody, suggesting virus replication dur-
ing infection. INOS was specifically expressed in
monocytes infected with DENV. Mock-infected mono-
cytes by inactivated DENV did not yield viral antigens dur-
ing culture. The inactivated virus consistently induced low
rates of INOS+ monocytes, however differences were sta-
tistically insignificant when compared to controls. The
infectious virus in all experiments resulted in significantly
higher rates of INOS+ monocytes than in control cultures.
Infectious virus, if not crucial, certainly play an important
role in inducing iNOS. Control cells displayed only low
levels of background labelling for both DENV-Ag and
iNOS.
During  in vitro infection DENV-Ag were markedly
expressed in monocytes and detected on day 3 either by
confocal microscopy (Figure 3B) or by flow cytometry
(Figure 4). However, from day 4 to 6 Ags detection disap-
peared rapidly (Figure 4E) with insignificant rates of
labelled cells (Student's T-test). INOS is apparently
detected in cells already at day 3, but it reaches signifi-
cantly higher frequencies of positive cells at days 5 and 6
(Figure 4E).
Frequencies of DENVAg+ and iNOS+ monocytes in dengue patients Figure 2
Frequencies of DENVAg+ and iNOS+ monocytes in dengue patients.Human PBMLs from dengue individuals were 
labelled with an antibody to DENV-Ag and an anti-mouse IgG-PE or with an antibody to iNOS FITC-labelled and data obtained 
by FACS in the monocyte gate. Percentages of DENV-Ag+ infected cells were determined in 11 healthy individuals and 35 with 
dengue (Figure 2A; 2 patients were measured in duplicate samples at different time points). Percentages of iNOS+ infected 
cells were determined in 10 healthy individuals and 22 with dengue (Figure 2B; 14 patients were measured in duplicate samples 
at different time points). Horizontal lines represent percentage averages of labelled cells from the population of individuals in 
each of the discrete categories.
control 1-5 6-10 11-20
0
10
20
30
40
50
60
i
N
O
S
+
c
e
l
l
s
(
%
)
control 1-5 6-11
0
15
30
45
D
E
N
V
+
c
e
l
l
s
(
%
)
A B
Time after disease onset (days)BMC Infectious Diseases 2005, 5:64 http://www.biomedcentral.com/1471-2334/5/64
Page 7 of 12
(page number not for citation purposes)
DENV-Ag detection in infected cells after treatment with 
an iNOS inhibitor – NGMLA or with a NO donor – SNP
Nitric oxide antiviral activity induced by viruses in mono-
nuclear phagocytes may be inhibited by N-monomethyl-
L-arginine acetate (NGMLA) [28]. Monocyte-enriched cul-
tures were treated with NGMLA and simultaneously
infected with DENV. DENV-Ag+ cells were present in sig-
nificantly higher frequency among infected cells in treated
cultures after 4 days, as compared to infected and
untreated cultures (Figure 5A, 5B). Figure 5A presents a
flow cytometry histogram with an increased DENV-Ag+
cell population in presence of NGMLA treatment as com-
pared to untreated infected cultures, with significantly
higher percentages of labelled cells (Figure 5B). Thus, the
inhibition of iNOS facilitates DENV-1 replication, sug-
gesting that NO production might be involved in the con-
trol of virus replication.
Dengue virus has limited rates of infection in monocytes
and after a few days infection is controlled accompanied
by the induction of several factors that may act as inhibi-
tors of viral replication [21,29]. Since C6/36 cells are
extremely susceptible to DENV infection and allow
intense virus replication, these mosquito cells should be
suitable to test the effect of a potential antiviral molecule.
Therefore, C6/36 cultures were infected with DENV and
simultaneously treated with sodium nitroprussiate (SNP),
a known NO donor, which was added at concentrations
of 10 or 100 µM. After 2 days of infection and treatment,
DENV-Ag+ cells were detected using FACS. An uninfected
cell control was used in order to detect unspecific label-
ling. SNP induced a significant inhibition of DENV-Ag
expression in infected C/36 cells in both tested concentra-
tions, when percentages of positive cells were compared
to those in untreated infected cells (analysis by Student's
T test; Figures 5C and 5D). Therefore, inhibition of DENV-
1 replication by NO production is evident during the
present experiments.
Discussion
DENV was detected for the first time by flow cytometry in
peripheral monocytes of infected patients. Earlier reports
demonstrated viral particles in monocytes, lymphocytes
or endothelial cells from tissues and blood clot of patients
[9,30]. Infectious DENV [3] or PCR detection of nucleic
acid [7] in PBMLs were even at higher incidence than in
serum. We did not detect viral antigens in lymphocytes
despite others having done so [9,30]. This may be due to
the viral strain used or alternatively the genetic
constitution of the human PBML donors. Monocytes are
important targets for DENV either in vitro [31] or in vivo
[8]. Supporting our previous report [26], we present here
that DENV likely replicates in monocytes since detected
antigens increase with time and no antigen is detected
when inactivated virus is used. This indicates that viruses
probably replicate for a short period and, during cell
infection, mechanisms are activated that are able to con-
trol further replication.
Interferon (IFN)-mediated antiviral action is still consid-
ered to be among the most important intracellular mech-
anisms against viruses, however recently a mechanism in
which viral proteins might be involved in blocking IFN
signalling during dengue virus infections has been
described [32] supporting the conjecture that other com-
plementary antiviral activities may be acting during den-
gue infection as well [33].
We have exhibited here that DENV can be detected in
peripheral monocytes of patients with acute Dengue
Fever, and that these cells are activated as demonstrated by
the expression of iNOS studied ex vivo. Equivalent data
was obtained with in vitro infected monocytes from
healthy individuals, and virus presence can be modulated
by inhibiting iNOS or generating NO in cell culture, indi-
cating that this molecule is likely to have a role in control-
ling DENV-1 genome expression within monocytes.
During acute Dengue Fever, iNOS expression in mono-
cytes differed among patients probably due to individual
variations. Inducible NOS is encoded by the NOS2A gene,
haplotype 2 is associated with self-limiting hepatitis C
infections [34] and NO production was associated with
less severe forms of dengue [19].
Viral replication inhibition by NO has been considered
with even increasing importance. The ability of NO to
inhibit virus replication was first described in 1993
Confocal microscopy of DENV-Ag expression after in vitro  infection of monocyte-rich cultures Figure 3
Confocal microscopy of DENV-Ag expression after in 
vitro infection of monocyte-rich cultures. Adherent 
human PBMLs were incubated for three days either with cell 
culture medium (Figure 3A, 189.5 µm/field), or with infec-
tious DENV (Figure 3B, 125 µm/field). Cells were labelled 
with antibody to DENV-Ag and anti-mouse IgG-FITC.BMC Infectious Diseases 2005, 5:64 http://www.biomedcentral.com/1471-2334/5/64
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DENV-Ag and iNOS expression after in vitro Dengue infection of monocytes Figure 4
DENV-Ag and iNOS expression after in vitro Dengue infection of monocytes. Adherent human PBMLs were incu-
bated for three days with infected DENV (Figures 4A, 4B and 4C). Cells were labelled either with isotype matched antibodies 
(Figures 6A and 6B) or antibodies to CD14-PE (y-axis) and DENV-Complex-Alexa-654 (x-axis) and were analysed by FACS 
(Figure 4C, ungated). Cells incubated for three to six days with cell culture medium, inactivated DENV or infectious DENV 
were labelled with antibody to DENV-Ag and anti-mouse IgG-PE and/or anti-iNOS-FITC and analysed by FACS. Isotype 
matched antibodies were used for both labelings (Figure 4D, 3 days for DENV-Ag and 6 days for iNOS labelling). x-axis repre-
sent mean of fluorescence intensity and y-axis represent percentage of maximum cell number counts. Figure 4E shows a kinetic 
curve comparing DENV-Ag and iNOS expression on cells from the monocyte gate. Each point represent average ± SEM per-
centages from samples set in triplicates. * P < 0.05 and in Student's T-test showing difference in DENV-Ag and iNOS expres-
sion compared to uninfected controls (CT). Data are obtained from one representative experiment out of three performed 
with different cell donors.
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Effect of an iNOS inhibitor and of a NO donor on DENV-Ag expression after cell infection Figure 5
Effect of an iNOS inhibitor and of a NO donor on DENV-Ag expression after cell infection. Figures 5A and 5B – 
Effect of iNOS inhibitor – NGMLA on monocyte infection. Adherent PBMLs were incubated with either Mock C6/36 cell 
supernatant or DENV inoculum for 4 days in presence or absence of 400 µM NGMLA. Figure 4A shows histogram with profile 
of infected monocytes after NGMLA treatment and labelling controls. Figure 4B shows percentages of DENV-Ag+ in gated 
monocytes obtained by flow cytometry. Figures 5C and 5D -. Effect of NO donor – SNP, on C6/36 cell infection. C6/36 cells 
were incubated with DENV for 2 days in absence or presence of 10 or 100 µM SNP. Figure 4C shows a histogram with profiles 
of infected C6/36 cells obtained by FACS from a culture treated with 10 µM SNP or controls. The histogram gates have been 
made where ≥99% than cells in the cell control are excluded. Figure 4Dshows percentages of DENV-Ag+ cells calculated from 
ungated cells after labelling with antibody to DENV-Complex and anti-mouse IgG-PE. In histograms x-axis represent mean of 
fluorescence intensity and y-axis represent percentage of maximum cell number counts. Cells were labelled with antibody to 
DENV-Complex followed by anti-mouse IgG-PE. Average ± SEM are represented from samples set in triplicates. * P < 0.05 in 
Student's T-test showing difference in DENV infection after treatment. Data are obtained from one representative experiment 
out of two for each cell type using two different monocyte donors.
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[33,35,36] and thereafter many other studies have been
developed. While some viruses were reported to be sus-
ceptible to NO action, others were resistant [35]. The
mechanisms by which NO induces viral modulation are
diverse, such as inactivation of viral cysteine protease by
NO-dependent S-nitrosylation [36] or inhibition of
Epstein-Barr virus reactivation. The inhibition of virus
replication by NO was found to be mediated by IFN-γ
[33,37] and dependent upon the induction of the signal
transducer and activator of transcription (STAT) STAT1
phosphorylation [38]. Antiviral NO-mediated effect may
also be activated by IFN-α, since it has been observed that
mononuclear leukocytes activated in vitro by IFN-α or
from Hepatitis C virus infected patients undergoing IFN-α
therapy produce NO [39]. Some flaviviruses had their NO
susceptibility tested and an effective inhibitory mecha-
nism was determined for Japanese encephalitis virus [40],
but studies on Tick-borne encephalitis virus (TBE-V)
revealed no antiviral effects by NO [35]. The fact that den-
gue patients may have monocytes activated by circulating
IFN-γ [12-14] is consistent with induction of iNOS during
acute disease as reported here for both in vivo and in vitro
infection.
NO may play a role in severity of viral hemorrhagic
fevers(Sanchez et al., 2004) probably when produced in
high concentrations, by affecting vascular tone and con-
tributing to virus-induced shock. As previously men-
tioned, NO was detected in sera from patients with
dengue [19] and correlated with the less severe form of the
disease. Hence, NO may be exerting both protective and
pathological action, depending upon the concentration
produced [41]. Since our panel consisted of few patients,
a correlation was not possible; iNOS+ cell rates were
increased in some patients from both groups presenting
mild or severe disease. Espina et al. [21] were not able to
detect NO production by monocytes in culture. This
apparent contradiction with our data of induced NOS
may be explained by the use of a diferent detection tech-
nique: Griess reagent detects nitrite in cell culture
supernatant which may be below method sensitivity since
the density of monocytes in culture is not high. We did
not succeed in detecting NO by this method in human
monocyte cultures, and we only detected NO in murine
macrophages after proper stimulation at high cell culture
density [20]. Moreover, detection of NO produced in vitro
by infected Kupffer cells [20] was carried out by a fluori-
metric assay, much more sensitive than the Griess
Reaction.
Only few reports show human mononuclear cells from
healthy individuals generating NO production following
treatment with cytokines, pathogens, and/or pathogen-
derived products [39,42]. Until a few years ago expression
of iNOS in humans was questioned [43] or difficult to
detect [20,44]. It may be possible that iNOS induction
and expression dependent on synergistic signals to macro-
phage/monocyte [45,46], and cytokines and virus prod-
ucts may be acting as different stimuli.
Replicating dengue viruses may be necessary for optimal
iNOS induction, since rates of iNOS+ cells were much
higher than when the inactivated virus was used. How-
ever, Kupffer cells infected with DENV induced NO and
iNOS, in spite of the absence of viral progeny. Non-living
products, such as peptides [47], originating from either
other viruses [39,48] or parasites [49,50] can stimulate
iNOS in macrophages/ monocytes and induce NO
production.
Our data demonstrate that, when experimentally infecting
their targets (e.g., monocytes), DENV-1 is able to induce a
progressive expression of the enzyme iNOS, indicating
that NO might be produced during in vitro infection as it
is produced in vivo. At 6 days of infection, the iNOS detec-
tion is increased as compared to that of 3 days and is
coincident with the DENV decrease, favouring the
hypothesis that iNOS+ cells were promoting an inhibitory
effect on viruses either directly by NO production or by
other virus-induced mechanisms during this monocyte
activation, such as IFN-α production [39]. Alternatively
cells interacting with viral antigens are probably becom-
ing activated and dying either by cell lysis or by virus
induced apoptosis [21]. We also observed that surviving
cells remained in culture for more than10 days : either
viruses are eliminated or cells become refractory by inter-
feron-related mechanisms, in contrast with what is
observed, e.g., for mosquito C6/36 cells, which are mostly
destroyed by the virus. Here we observed that there is an
enhancement of DENV-1 Ags detection, when infected
monocytes were cultured with the iNOS inhibitor
NGMLA, indicating that DENV-1 is very likely susceptible
to NO inhibitory activity. This result is confirmed by the
observation that DENV-1 detection is strongly inhibited
in C6/36 cultures by the presence of the NO donor, SNP.
These findings are similar and supported by observations
in other viral models [51].
With regard to DENV replication, further studies are war-
ranted in order to elucidate which pathways are involved
in NO-mediated inhibition of DENV-1. Despite C6/36
remain viable by Trypan blue or propide iodine exclu-
sions, it has to be considered that the NO action in virus
targeted cells may involve apoptosis. Furthermore, it is
not known whether or not other strains and serotypes will
activate iNOS and be sensitive to NO action. There may be
relevance in studying various strains from different sero-
types and evaluate if susceptibility and resistance are
strain and/or serotype specific.BMC Infectious Diseases 2005, 5:64 http://www.biomedcentral.com/1471-2334/5/64
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Conclusion
The data presented here displays for the first time the pres-
ence of iNOS in monocytes from patients with acute den-
gue fever. Despite the fact that, in excess, NO may provide
a deleterious effect on vascular permeability, evidence
exhibited here favour a role for NO in the control of in
vitro dengue infection within monocytes. This may hold
true for natural human infection as well.
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